Abstract: The diastereoselective, trichlorosilane-mediate reduction of imines, bearing different and removable chiral auxiliaries, in combination either with achiral bases or catalytic amounts of chiral Lewis bases, was investigated to afford immediate precursors of chiral APIs (Active Pharmaceutical Ingredients).
Introduction
Rasagiline mesylate (Figure 1 ), also known as (R)-(+)-N-propargyl-1-aminoindan mesylate, is a commercially marketed pharmaceutically active substance, under the brand name azilect®. The racemic form of the drug was patented by Aspro Nicholas in the early 1979, and was later found to be indicated for treatment of Parkinson's disease (PD), being effective both as monotherapy in early PD, and as adjunctive in patients with advancing PD and motor fluctuations. [1] This chiral amine is a potent second-generation propargylamine pharmacophore that selectively and irreversibly inhibits the B-form of the monoamineoxidase enzyme (MAO-B) over type A by a factor of fourteen. [2] European drug-regulatory authorities approved this potent MAO-B inhibitor in February 2005 and the US FDA in May 2006. [3] Although the S-(−)-enantiomer of N-propargyl-1-aminoindane still exerts some neuroprotective properties, the potency of R-(+)-enantiomer against the MAO-B enzyme is approximately 1000-fold higher. Different strategies aimed to the preparation of the enantiopure compound have been explored, [4] but, at the best of our knowledge, a stereoselective organocatalytic approach for the preparation of rasagiline has never been reported so far. We report here a metal-free stereoselective strategy for the synthesis of rasagiline and of an advanced intermediate of another API, tamsulosin, sold under the trade name flomax as single enantiomer. Active as antagonist for α1a adrenergic receptor, It is used to treat symptomatic benign prostatic hyperplasia and to treat urinary retention. Starting from this common precursor, different pharmaceutically active compounds could be prepared, having as biological targets different receptors such as cholinesterase and monoamine oxidase inhibition [5] , σ-receptors [6] and human adenosine A2A receptor. [7] The synthetic plan for the preparation of the two-target molecules involves a metal-free stereoselective reduction of imines, easily prepared starting from commercially available ketones (Scheme 1). [8] Scheme 1. Synthetic strategy for the synthesis of rasagiline and tamsulosin.
Results and Discussions
We initially explored the possibility to use a catalytic amount of chiral Lewis base (LB) for the stereoselective, trichlorosilane-mediated reduction of the imine prepared starting from 1-indanone. Two different chiral picolinamides, previously developed in our group, were tested.[9-10] Using ephedrine-derived catalyst A, the chiral amines were obtained in high yields, both using PMP (paramethoxyphenyl) and benzyl protected imines, but with modest enantioselectivities, up to 60%. e. Reductions were performed starting from a diastereoisomeric mixture of imine 3, prepared from 1-(R)-phenylethylamine in a 9:1 (3c:3d) ratio, in favor of the E imine 3c. The best results were achieved working at -20°C, and performing the reaction for 36h; the product was obtained in 55% yield and 98:2 diastereomeric ratio in favor of the (R,R) stereoisomer 4c (Table 1 , entry 5). To achieve complete conversion higher reaction temperature were needed (Table 1 , entry 6), leading to a small decrease of diastereoselection (90:10 of d.r.). Finally, in the attempt to increase further the efficiency of the process, the use of a match combination between the chiral auxiliary and the chiral catalyst was investigated. Based on previous works, [9] we selected the known favorable combination of catalyst A and 1-(R)-phenylethylamine as chiral auxiliary: the reduction was accomplished in 90% conversion and a 90:10 of d.r. ratio (Table 1 , entry 7). Since the use of catalyst B, that leads to formation of products of (S) configuration,[10] afforded, as expected, the product in lower stereoselectivity (entry 8, mismatch couple with the chiral auxiliary that favours the formation of product with (R) configuration), the use of pseudo-enantiomer of catalyst B allowed to obtain the product 4c in 80% conversion and a complete diasteroselectivity (Table 2, entry 9).
With the best reaction conditions in our hands, we decided to explore the possibility of employing different chiral auxiliaries. Since the removal of the α-methylbenzylamine tipycally requires palladium catalysts, [11] we focused our attention onto the use of a chiral auxiliary removable without the need of precious transition metals. In particular, we selected commercially available (R)-4-methoxy-α-methylbenzylamine and (R)-2-methyl-2-propanesulfinamide since they could be removed under metal-free conditions. [12] , [13] Imines 5a and 6a were readily synthesized and their reduction was performed in the presence of 3.5 mol eq. of trichlorosilane and stoichiometric amounts of DMF or catalytic amounts of chiral picolinamide A (see Scheme 4).
Imine 5a was efficiently reduced using DMF as achiral LB (Table 2 , entry 1), with high conversion (80 %) and a complete diasteroselectivity. In order to increase the yield, the reaction was then performed in the presence of catalyst A (Table 2, entry 2); complete conversion of the starting material into the chiral amine 5b and a total stereocontrol of the reaction were observed. Analogously, the reduction of imine 6a was efficiently promoted by catalyst A, affording the product 6b, that was in situ deprotected during the basic aqueous work up, to afford the primary chiral amine 1 in quantitative yield and 60% e.e. (entry 4, Table 2 ). Running the reduction of imine 5a at low temperature (17°C), low conversions were detected; when the reaction was performed at 30°C, the product was isolated in 83% yield but, as expected, with a lower disatereoisomeric ratio (92:8, entry 4, Table 3 ). In order to achieve a complete stereocontrol, the reaction was run in the flow reactor in the presence of catalyst A; operating at 30°C and with a 30 min. residence time, the matching combination of an enantiopure catalyst with the chiral auxiliary, the chiral amine 5b was in continuo produced in 70% yield as stereoisomerically pure compound (entry 5, Table 3 ). The synthesis of an advanced intermediate of tamsulosin was then studied. By following the same synthetic approach and taking advantage of the previously used chiral auxiliaries, enantiopure imines 7a and 8a were synthesized and their reduction studied in batch (Scheme 6).
Scheme 6. In batch synthesis of advanced precursors of tamsulosin.
The results are reported in Table 4 ; when using an achiral base (DMF), the reduction of imine 7a proceeds with a modest diastereoselectivity, and only with catalyst B an improved stereocontrol was obtained, although the product was isolated in 50% yield only. However, starting from chiral imine 8a better results were achieved; simply using a combination of two very cheap reagents, like trichlorosilane and N,Ndimethylformamide, the primary amine 2 was directly obtained after the work up in quantitative yield and 94% e.e. (entry 9, Table 4 ). the product was obtained as primary amine directly after the work up; e.e. was determined by HPLC on chiral column (see the Supporting Information)
The reaction was then performed in the previously described flow reactor system (Scheme 7); with imine 7a the in-flow reduction nicely reproduced the results of the in batch procedure (entries 1-2, Scheme 7. In-flow synthesis of chiral amine 2, a tamsulosin precursor.
When enantiopure imine 8a was reduced with DMF and trichlorosilane in the PTFE flow reactor, the chiral primary amine 2 was directly produced and was collected out from the flow reactor, after in line basic aqueous work up, in 70% isolated yield and 88% e.e. (entries 3-4, Table 5 ). In the present study, a stereoselective, metal-free strategy for the synthesis of chiral amines, direct precursors of rasagiline and tamsulosin, was developed. After setting up the reaction conditions in batch, the stereoselective trichlorosilane-mediated reduction of chiral imines was efficiently performed under continuous flow conditions. Chiral primary amines were obtained either by a continuous flow hydrogenolysis, or directly out from the flow reactor after an in-line aqueous work up, depending on the chiral auxiliary group at the amine nitrogen atom.
The present work represents a further step towards the development of a multistep continuous flow process for the synthesis of enantiomerically pure pharmaceutically relevant amines.
